glp-1's GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Synthetic Peptide Analog |

Jastreboff, A

In the United States, an estimated 30 percent of people between ages 50 and 59 have diverticulosis, and that number rises to more than 70 percent for people over age 80

Originally created to help people living with type 2 diabetes, drugs like Zepbound and Wegovy have skyrocketed in popularity for their powerful effects on weight loss

Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history

This is a federal requirement under the Medicaid Drug Rebate Program states cannot exclude FDA-approved diabetes drugs from their formularies